Renal Cell Carcinoma: Histopathological and Molecular Classification Guidelines
Diagnostic Approach
- Core needle biopsy or surgical specimen provides definitive histologic classification with a sensitivity of 86‑100 % and specificity of 98‑100 %. 4
- Tissue acquisition (core needle biopsy → systemic therapy; nephrectomy → definitive diagnosis) is the preferred initial step for patients with metastatic disease or prior to ablative therapies. 4
- Histopathological confirmation is mandatory before initiating systemic treatment; imaging alone cannot reliably determine RCC subtype. 4
Histologic Subtypes
| Subtype | Approximate Frequency | Key Morphologic Features | Molecular Correlates |
|---|---|---|---|
| Clear cell RCC | 70‑85 % | Cells with clear cytoplasm (glycogen + lipid), tubular/solid growth, prominent capillary stroma | VHL gene mutations; 3p25‑26 chromosomal loss |
| Papillary RCC | 7‑15 % | Papillary architecture around capillary cores; strong α‑methylacyl‑CoA racemase expression | Type I: c‑MET mutations; Type II: SETD2 or FH mutations |
| Chromophobe RCC | 5‑10 % | Polygonal cells with clear cytoplasmic membranes; pale reticulated cytoplasm with 150‑300 nm vesicles; diffuse CK7 positivity distinguishes from oncocytoma | Chromosomal losses of 1, 2, 6, 10, 13, 17, 21 |
- The ISUP nucleolar grading system (grades 1‑4) should be applied to clear cell and papillary RCC. 1
- Presence of sarcomatoid or rhabdoid differentiation upgrades the tumor to grade 4. 1
- Documentation of necrosis, microscopic vascular invasion, and pTNM stage is required for all RCC specimens. 1
Molecular Subtypes (Emerging Standard)
The 2022 WHO classification defines 11 molecular‑defined RCC subgroups that cannot be diagnosed by morphology alone and require molecular testing (e.g., immunohistochemistry, FISH, NGS). 3
MiT family translocation RCC – should be excluded in patients < 40 years with papillary or complex architecture; diagnosis requires IHC and FISH for TFE3/TFEB rearrangements. 2
FH‑deficient RCC – associated with hereditary leiomyomatosis‑RCC syndrome; typically presents as type 2 papillary RCC with a poor prognosis. 1
SDH‑deficient RCC – requires dedicated molecular assays for SDH gene loss. 3
ALK‑rearranged RCC – identification directs the use of ALK‑targeted inhibitors. 9
Prognostic Genomics in Clear Cell RCC
- PBRM1 mutations – linked to stage III features but generally indicate a favorable prognosis. 9
- BAP1 mutations – associated with larger tumors, higher nuclear grade, and inferior cancer‑specific survival. 9
- SETD2 mutations – correlate with increased tumor aggressiveness. 9
- MTOR mutations – predict sensitivity to mTOR inhibitors (e.g., everolimus, temsirolimus). 9
Treatment‑Related Implications
- Identification of ALK rearrangements or MTOR mutations guides selection of targeted therapies (ALK inhibitors, mTOR inhibitors). 9
- Molecular confirmation of FH‑deficient or SDH‑deficient RCC informs eligibility for specific clinical trials or metabolic‑targeted strategies. [1][3]
Common Pitfalls to Avoid
- Do not rely solely on imaging to assign RCC subtype; histopathology is required before systemic therapy. 4
- Do not omit biopsy in metastatic disease, even when nephrectomy is planned, to ensure appropriate treatment selection. 4
- Do not use outdated Fuhrman grading; the ISUP nucleolar grading system is the current standard for clear cell and papillary RCC. 1
- Do not let fear of tumor seeding deter biopsy; seeding events are rare and should not preclude tissue diagnosis. 1